HCG Diet NJ (NJ Weight Loss & Preventive Care Clinics PA)
Voorhees main office · 1605 Evesham Road, Suite LL1 · Voorhees, NJ 08043
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
About this practice
HCG Diet NJ is a self-pay, physician-monitored HCG diet program of NJ Weight Loss & Preventive Care Clinics PA (medical director Daniel Olivero, MD), with offices in Voorhees and Fairfield, NJ, plus telemedicine after a required in-office start. The official site sells all-inclusive HCG packages using Pregnyl (Organon) HCG with B12, 24/7 nurse support, and a very-low-calorie protocol; it compares their HCG experience to GLP-1s but does not offer semaglutide or tirzepatide. Insurance is not accepted.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Yes |
| Cash pay accepted | Yes |
| Accepts insurance — per practice website | Not listed |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Clinicians
- Daniel Olivero, MD
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs